HOME >> BIOLOGY >> NEWS
New Company To Turn UNC-CH, Army Inventions Into Improved Vaccines

By ELIZABETH ZUBRITSKY
UNC-CH News Services

CHAPEL HILL -- Inventions by microbiologists at the University of North Carolina at Chapel Hill and U.S. Army Medical Research Institute of Infectious Diseases have led to creation of AlphaVax, a new company in Durham.

UNC-CH has licensed exclusively to AlphaVax four patents and two applications for patents expected to be issued. The company will develop and market the technology, which has broad applications for vaccines and gene therapy, company officials say. Initial targets include infectious diseases such as HIV -- the virus that causes AIDS -- herpes simplex virus and human papilloma virus.

Dr. Robert E. Johnston, UNC-CH professor of microbiology and immunology and one of the company's founding scientists, said the technology has obvious advantages over other vaccine methods. The new technique is efficient -- delivering large amounts of immunity-provoking substances directly to critical tissues -- and can be used multiple times in the same patient, Johnston said.

The approach grew out of research on the life cycle of the Venezuelan equine encephalitis virus done by Johnston, his UNC-CH colleague Dr. Nancy Davis and the Army institute?s Dr. Jonathan Smith. All AlphaVax scientific founders, the researchers created disarmed versions of the virus, which stimulated the immune system but did not cause disease. They also turned the attenuated virus into a vector -- a delivery vehicle that can be used for many kinds of vaccines. Unlike most vectors, however, this one can be used in the same patient several times.

"Many vectors don't work well if reused because the immune system reacts to them," said Davis, research associate professor of microbiology and immunology. "So far, in our studies in rodents, we haven't run into that problem. We're able to use our vectors for multiple vaccines or booster sh
'"/>

Contact: David L. Williamson
rdtokids@email.unc.edu
919-962-8596
University of North Carolina at Chapel Hill
22-Jan-1998


Page: 1 2

Related biology news :

1. Ferr-Damar wins 2004 Eli Lilly and Company Research Award
2. Open access initiative from the Company of Biologists
3. ESA Corporate Award winner 2001: Weyerhaeuser Company Limited British Columbia Coastal Forest Project Team
4. Warner-Lambert Company gift creates bioinformatics program
5. SFU Spin-Off Company To Research Promising Antibacterial Agents
6. New Company Formed Through Licensing Of Cardiac-Hypertrophy Technology From Texas Institutions
7. Move Over, Protein Kinase C, Youve Got Company: Munc13-1 Is A Novel Diacylglycerol Target That Modulates Neurotransmitter Release
8. Perkin-Elmer, Dr. J. Craig Venter, And TIGR Announce Formation Of New Genomics Company
9. Florida Company Using ORNL Technology For Revolutionary Wheelchair
10. Hopkins Engineering Undergrads Inventions: Power Tools For Double Amputee, Military Surveillance Robot
11. Improved nutrition could reduce malaria burden worldwide

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: New Company Turn UNC Army Inventions Into Improved Vaccines

(Date:7/25/2014)... a pleiotropic factor characterized by the existence of ... that confer to the protein deeply different characteristics. ... myelination occurring during development and the different phases ... degeneration, axon regrowth, remyelination and target reinnervation, Researchers ... that the soluble NRG1 upregulation observed in Schwann ...
(Date:7/25/2014)... of a molecular testing panel developed at UPMC ... initial surgery for patients with thyroid nodules and ... Cancer Institute (UPCI), partner with UPMC CancerCenter., The ... and other diagnostic testing agencies, improved the chances ... 30 percent, according to the study published this ...
(Date:7/24/2014)... -- Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX) (the "Company") announced the ... Phase 3 study of Zerenex (ferric citrate), the Company,s ... of hyperphosphatemia in patients with end-stage renal disease (ESRD) ... delivery with FErric CiTrate in EsrD) was published online ... of Nephrology ( JASN ). , ...
Breaking Biology News(10 mins):Test increases odds of correct surgery for thyroid cancer patients 2Test increases odds of correct surgery for thyroid cancer patients 3Zerenex™ (ferric citrate) long-term Phase 3 study results published in JASN 2Zerenex™ (ferric citrate) long-term Phase 3 study results published in JASN 3Zerenex™ (ferric citrate) long-term Phase 3 study results published in JASN 4
(Date:7/24/2014)... MENLO PARK, Calif. , July 24, 2014 ... biotechnology company in the emerging field of regenerative ... live webcast of a presentation to investors on ... 1:30 p.m. PDT.  The presentation will include an ... pipeline. To access the webcast, visit http://www.ustream.tv/channel/asterias-biotherapeutics ...
(Date:7/24/2014)... Yet, scientists are making progress in devising suitable ... approach relies on quantum dotsa kind of artificial ... A new study demonstrates that changing the coupling ... electrical impulses can help better control them. This ... as quantum information units, which would produce faster ...
(Date:7/24/2014)... 24, 2014 Research and Markets ... and Proteomics Analytical Instruments Market 2014-2018" report to ... Genomics is the study of the gene ... the structure and functions of proteomes or sets of ... technology. Genomics involves the mapping of genes and DNA ...
(Date:7/24/2014)... Three companies from the angelMD network were ... Competition. Out of 700 competition entrants, Chiron Health, Litesprite, ... round. In this round twenty teams are invited to ... mentoring from thought-leaders and medical entrepreneurs from all over ... commitment to the Livestrong vision around the Big C ...
Breaking Biology Technology:Asterias Biotherapeutics Announces Live Investor Webcast 2Asterias Biotherapeutics Announces Live Investor Webcast 3Asterias Biotherapeutics Announces Live Investor Webcast 4Global Genomics and Proteomics Analytical Instruments Market 2014-2018: Key Vendors are Agilent, Bio-Rad , F. Hoffmann, La Roche, Illumina, PerkinElmer and Thermo Fisher Scientific 23 angelMD Startups Make Livestrong Big C Semi-finals 2
Cached News: